Skip to content

Clinical study on Prevention and treatment of Vascular dementia by invigorating spleen and Kidney, resolving phlegm and dredging collaterals

Clinical study on Prevention and treatment of Vascular dementia by invigorating spleen and Kidney, resolving phlegm and dredging collaterals

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004618
Enrollment
Unknown
Registered
2021-03-23
Start date
2017-02-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Demantia

Interventions

Sponsors

Shenzhen TCM Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 50 years old and = 7 points. 3.Clinical dementia scale (CDR) score >= 0.5,Montreal Cognitive Assessment scale (MoCA) score = 7; 4. He hasn't taken any drugs for dementia in 42 weeks. 5. Voluntarily and sign informed consent, with good compliance.

Exclusion criteria

Exclusion criteria: 1.Dementia caused by Alzheimer's disease or other causes diagnosed by DSM-5 standard. 2. Patients with 2HIS score 17. 4.Patients with severe medical diseases or severe neurological impairment, such as malignant tumors, various aphasia, visual and auditory disorders, etc.; patients with liver, kidney or heart diseases, including those with ALT or AST more than 3 times normal, cardiac function grade 2-4, serum creatinine (Scr) > 177 umol / L; patients with cognitive impairment, such as tumors, AIDS, hyperthyroidism, and patients with severe anemia. Patients with unstable control of metabolic diseases; patients with underlying diseases such as asthma or chronic lung disease, or patients with polyneuritis, myasthenia gravis and muscular atrophy who may have sudden asphyxia; patients with severe gastrointestinal diseases or diseases that affect drug absorption, such as severe dyspepsia, gastrointestinal obstruction, duodenal ulcer, etc.; patients with glaucoma that affect visual function evaluation. Have a history of epilepsy and encephalitis, and related diseases that lead to dementia, such as Huntington's disease, Parkinson's disease, etc.; patients who interfere with the evaluation of cognitive diseases, such as alcoholism, previous drug abuse and drug abusers; patients with severe neurological deficiency with impact evaluation; patients whose heart rate is not in the range of 50-110 beats / min and have developed heart diseases such as myocardial infarction and arrhythmia within 4 months. The systolic blood pressure of patients in sitting position and supine position was not in the range of 100-180 mm Hg. 5. The age of the patients is less than 50 years old, or the course of disease is not enough. 6. Those who had a history of drug allergy or participated in other drug trials within 2 months.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment, MoCA;

Secondary

MeasureTime frame
SDSVD;

Countries

China

Contacts

Public ContactGuo Zhouke

Shenzhen Traditional Chinese Medicine Hospital

szzyygzk@126.com+86 13688806589

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026